liu.seSearch for publications in DiVA
Change search
ReferencesLink to record
Permanent link

Direct link
Sertraline versus paroxetine in major depression: Clinical outcome after six months of continuous therapy
Linköping University, Faculty of Health Sciences. Linköping University, Department of Neuroscience and Locomotion, Psychiatry. Östergötlands Läns Landsting, Local Health Care Services in Central Östergötland, Department of Psychiatry.
Show others and affiliations
2000 (English)In: Journal of Clinical Psychopharmacology, ISSN 0271-0749, Vol. 20, no 6, 645-652 p.Article in journal (Refereed) Published
Abstract [en]

Relatively little research is available comparing the efficacy and tolerability of selective serotonin reuptake inhibitors (SSRIs) during continuation therapy. This investigation reports the differential effect of 6 months of treatment with sertraline versus paroxetine for symptoms of depression, quality of life, and personality outcomes. Outpatients with unipolar major depression (DSM-III-R) were randomly assigned to receive 24 weeks of double-blind treatment with flexible doses of paroxetine (20-40 mg) or sertraline (50-150 mg). Assessments included the Montgomery-Asberg Depression Rating Scale (MADRS), the Clinical Global Impression Scale, the Battelle Quality of Life Questionnaire, and the Structured Clinical Interview for DSM-III-R Personality Disorders screen questionnaire. One hundred seventy-six patients (mean age, 43 years, 64% female, baseline MADRS, 30.3) were treated with sertraline and 177 patients (mean age, 42 years, 71% female, MADRS, 30.7) with paroxetine. Antidepressant efficacy during continuation therapy was sustained, with only 2% of patients receiving sertraline and 9% of patients receiving paroxetine suffering a relapse. Continuation therapy resulted in a substantial conversion of responders during short-term treatment to full remission: remitter rates increased from 52% to 80% for sertraline and from 57% to 74% for paroxetine. The improvements in quality of life were related to a reduced depression score. SSRI treatment had significant beneficial effects on both categorical and dimensional measures of personality. A logistic regression analysis identified early response (25% reduction in MADRS scores at week 2) as the most important predictor of treatment response, whereas high severity, chronicity, and poor baseline quality of life had no effect. Both treatments were well-tolerated, with sertraline having a somewhat lower side effect profile. Sertraline and paroxetine demonstrated comparable efficacy during short-term and continuation therapy. Treatment was associated with significant improvement in quality of life and with reductions in axis II personality psychopathology.

Place, publisher, year, edition, pages
2000. Vol. 20, no 6, 645-652 p.
National Category
Medical and Health Sciences
URN: urn:nbn:se:liu:diva-27661DOI: 10.1097/00004714-200012000-00010Local ID: 12399OAI: diva2:248213
Available from: 2009-10-08 Created: 2009-10-08 Last updated: 2011-01-14

Open Access in DiVA

No full text

Other links

Publisher's full text

Search in DiVA

By author/editor
Bengtsson, Finn
By organisation
Faculty of Health SciencesPsychiatryDepartment of Psychiatry
In the same journal
Journal of Clinical Psychopharmacology
Medical and Health Sciences

Search outside of DiVA

GoogleGoogle Scholar
The number of downloads is the sum of all downloads of full texts. It may include eg previous versions that are now no longer available

Altmetric score

Total: 38 hits
ReferencesLink to record
Permanent link

Direct link